ANDA 206630, held by Chartwell Rx. Potassium Chloride.
As of Nov 15, 2026, ANDA 206630 (Potassium Chloride), held by Chartwell Rx, was first approved by FDA on Mar 29, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2019 | Original application | Approved | None posted |
| Potassium Chloride10MEQ · tablet, extended release;oral | Potassium Chloride | Discontinued |
| Potassium Chloride15MEQ · tablet, extended release;oral | Potassium Chloride | Discontinued |
| Potassium Chloride20MEQ · tablet, extended release;oral | Potassium Chloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
